Research Reports

Key takeaways

Revenue was $309.9M, up 14.9% year-over-year, reflecting continued demand for medication management solutions across care settings.

Gross profit was $140.4M, up 26.5% year-over-year, as cost of product revenues grew at a slower pace than product revenues due to scale and installation efficiencies, favorable product mix, and tariff impacts.

Operating income was $16.9M, a significant improvement from a $11.6M loss in Q1 FY2025, signaling restored operational leverage.

Net income was $11.4M (EPS $0.25), reversing a $7.0M loss (EPS -$0.15) in Q1 FY2025, supported by higher gross profit and controlled operating expenses.

Net cash provided by operating activities was $54.5M, more than double the $25.9M in Q1 FY2025, reflecting improved working capital execution and earnings quality.

Free cash flow was $42.1M, calculated as operating cash flow less capital expenditures of $12.4M, underscoring sustainable cash generation capacity.

Full analysis

Gross profit rose 26.5% year-over-year to $140.4 million, outpacing revenue growth and resulting in a gross margin of 45.3%. This expansion reflects the favorable impact of scale and efficiencies in installations, as well as product and customer mix — though partially offset by tariffs during the period. Notably, the increase in cost of product revenues did not rise proportionally with the increase in product revenues, supporting margin resilience despite external cost pressures.

Operating income improved dramatically to $16.9 million, compared to a $11.6 million loss in Q1 FY2025. This turnaround reflects both top-line momentum and disciplined management of operating expenses. Net income followed suit, reaching $11.4 million ($0.25 per diluted share), reversing a $7.0 million loss ($-0.15 per diluted share) in the prior-year quarter.

OMCL · Omnicell, Inc.

Summary

Key takeaways

Full analysis